SCHEMBL1403532

SCHEMBL1403532

O=C(C=Cc1cccc(S(=O)(=O)Nc2ccc3ccccc3c2)c1)NO

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 19/20 0.80
HDAC8 Q9BY41 18/20 0.76
HDAC2 Q92769 16/20 0.76
HDAC6 Q9UBN7 16/20 0.76
HDAC3 O15379 15/20 0.76
HDAC4 P56524 15/20 0.76
HDAC7 Q8WUI4 15/20 0.76
HDAC10 Q969S8 15/20 0.76
HDAC11 Q96DB2 15/20 0.76
HDAC9 Q9UKV0 15/20 0.76
HDAC5 Q9UQL6 15/20 0.76
BRD4 O60885 1/20 0.76
ESR1 P03372 1/20 0.76
PTGS1 P23219 1/20 0.76
PDE4A P27815 1/20 0.76
PIK3CA P42336 1/20 0.76
HTR6 P50406 1/20 0.76
PDE4D Q08499 1/20 0.76
ASPH Q12797 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403531 1.00 HDAC1 (0.80) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL1403546 0.89 HDAC1 (0.91) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL1403548 0.89 HDAC1 (0.91) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL5047233 0.89 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL1403172 0.88 AKR1C3 (0.64) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL1403175 0.88 AKR1C3 (0.64) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL1403019 0.87 HDAC1 (0.61) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL1403017 0.87 HDAC1 (0.61) HDAC1HDAC8HDAC2HDAC6HDAC3
Belinostat SCHEMBL375906 0.87 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3
Belinostat SCHEMBL29379950 0.87 HDAC1 (1.00) HDAC1HDAC8HDAC2HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292593-A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2011-03-09 EP disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 US disclosed
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-07-03 US disclosed
US-7183298-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-02-27 US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 US disclosed
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors PROLIFIX LIMITED (GB) 2005-05-19 US disclosed
US-6888027-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2005-05-03 US disclosed
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPO TARGET UK LIMITED, (GB) 2005-04-21 US disclosed
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors SWK FUNDING LLC 2004-04-22 US disclosed
EP-1328510-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LTD. (GB) 2003-07-23 EP disclosed
WO-2002030879-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC2 5/4885
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC2 5/4885
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC2 5/4885
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors HDAC1, HDAC11, HDAC2 HDAC1 1/4885HDAC8 4/4885HDAC2 3/4885
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 4/4885HDAC2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.